Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria: * Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention * At least three months from the last dose of neurotoxic cancer-directed drug * No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment * Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment * \> Six-month life expectancy * Able to complete questionnaires by themselves or with assistance * Able to provide informed written consent * ECOG Performance Status score ≥ two * Not currently enrolled in another research study for pain or neuropathy Exclusion Criteria: * Pregnant or nursing * An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and/or medical monitoring device * History of myocardial infarction or ischemic heart disease within six months of trial enrollment * History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure * Skin conditions such as open sores that will prevent proper application of electrodes * Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST * History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy * Prior treatment with Scrambler Therapy * The presence of chronic regional pain syndrome (CRPS) in the scrambler therapy treatment area.